Patent Pool Strikes Deals with Cipla, Pfizer For New HIV, TB Drugs
The Medicines Patent Pool, a UN-backed public health organization, has announced deals with two major global pharma firms aimed at providing innovative, effective and affordable treatment for people - including children - living with HIV and TB.
You may also be interested in...
Pfizer and the Medicines Patent Pool have signed a licensing agreement for the US firm’s investigational TB compound, sutezolid. The move should help to speed up the availability of the product, whose development appears to have been stalled since 2013.
A new licensing deal between the Medicines Patent Pool and a leading academic center for a Phase II tuberculosis drug candidate originally in development by Pfizer could signal a real opportunity for getting a commercially challenging product to market. Public health groups, while welcoming the move, have noted that the deal is no guarantee that the medicine will actually reach the patients who need it, though.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.